Literature DB >> 11826411

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome.

Shivakumar Chitturi1, Shehan Abeygunasekera, Geoffrey C Farrell, Jane Holmes-Walker, Jason M Hui, Caroline Fung, Rooshdiya Karim, Rita Lin, Dev Samarasinghe, Christopher Liddle, Martin Weltman, Jacob George.   

Abstract

Nonalcoholic steatohepatitis (NASH) is often linked with disorders that are clearly associated with insulin resistance (IR): obesity, type 2 diabetes mellitus, and hypertriglyceridemia. We tested the hypotheses that (1) IR is an essential requirement for the development of NASH and (2) a high association between IR and liver disease is relatively specific for NASH. We measured body mass index (BMI), waist/hip ratio, and fasting serum lipid, insulin, C-peptide, and glucose levels in 66 patients with NASH (21 with advanced fibrosis and 45 with mild fibrosis). IR was determined by the homeostasis model assessment (HOMA). We also determined the strength of the association of NASH with insulin resistance syndrome (IRS) as defined by World Health Organization criteria. To assess whether the finding of IR was relatively specific to NASH rather than simply to obesity or liver disease, we compared the results of a subset of 36 patients with less-severe NASH with 36 age- and sex-matched patients with chronic hepatitis C virus (HCV) of comparable fibrotic severity. IR was confirmed in 65 patients (98%) with NASH, and 55 (87%) fulfilled minimum criteria for IRS. IR was found in lean as well as in overweight and obese patients. The IR values and the prevalence of IRS (75% vs. 8.3%) were significantly higher in those with NASH than in comparable cases of HCV. Hyperinsulinemia was attributable to increased insulin secretion rather than decreased hepatic extraction. In conclusion, most patients with NASH have IRS, and there is a near-universal association between NASH and IR irrespective of obesity. IR is present in mild as well as advanced cases of NASH but is unusual in chronic HCV of similar fibrotic severity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11826411     DOI: 10.1053/jhep.2002.30692

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  273 in total

1.  Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey.

Authors:  Lei Shen; Jian-Gao Fan; Yan Shao; Min-De Zeng; Jun-Rong Wang; Guo-Hao Luo; Ji-Qiang Li; Si-Yao Chen
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

2.  Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program.

Authors:  Cary H Patt; Hwan Y Yoo; Kourosh Dibadj; John Flynn; Paul J Thuluvath
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

3.  Histological resolution of steatohepatitis after iron depletion.

Authors:  Arnoldo Riquelme; Alejandro Soza; Leyla Nazal; Gabriel Martínez; Marianne Kolbach; Alejandro Patillo; J Marcos Arellano; Ignacio Duarte; Jorge Martínez; Monserrat Molgó; Marco Arrese
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

Review 4.  Impact of liver diseases on the development of type 2 diabetes mellitus.

Authors:  Po-Shiuan Hsieh; Yen-Ju Hsieh
Journal:  World J Gastroenterol       Date:  2011-12-28       Impact factor: 5.742

5.  Non-alcoholic fatty liver disease: is iron relevant?

Authors:  Julia O'Brien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2011-08-12       Impact factor: 6.047

6.  Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice.

Authors:  Kouichi Miura; Yuzo Kodama; Sayaka Inokuchi; Bernd Schnabl; Tomonori Aoyama; Hirohide Ohnishi; Jerrold M Olefsky; David A Brenner; Ekihiro Seki
Journal:  Gastroenterology       Date:  2010-03-27       Impact factor: 22.682

7.  Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice.

Authors:  Anisha A Gupte; Joey Z Liu; Yuelan Ren; Laurie J Minze; Jessica R Wiles; Alan R Collins; Christopher J Lyon; Domenico Pratico; Milton J Finegold; Stephen T Wong; Paul Webb; John D Baxter; David D Moore; Willa A Hsueh
Journal:  Hepatology       Date:  2010-10-11       Impact factor: 17.425

8.  Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  Hüseyin Saadettin Uslusoy; Selim Giray Nak; Macit Gülten
Journal:  World J Hepatol       Date:  2011-08-27

9.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms.

Authors:  E Bugianesi; A Gastaldelli; E Vanni; R Gambino; M Cassader; S Baldi; V Ponti; G Pagano; E Ferrannini; M Rizzetto
Journal:  Diabetologia       Date:  2005-03-04       Impact factor: 10.122

10.  Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.

Authors:  Zvi Ackerman; Mor Oron-Herman; Talma Rosenthal; Orit Pappo; Gabriela Link; Ben-Ami Sela; Maria Grozovski
Journal:  Dig Dis Sci       Date:  2007-08-22       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.